Amadis Partners with Groupe BPCE’s PayPlug Division for First Worldwide nexo standards-based SoftPOS Application
28.3.2022 08:00:00 EEST | Business Wire | Press release
PayPlug (part of the Payment activities of Groupe BPCE) selects Amadis, a global payment software editor, to deploy its nexo based payment acceptance application, on an array of traditional payment terminals and Android SoftPOS devices, through a standardized payment acceptance approach, independent of EMV® Level 2 card processing frameworks. This drastically reduces deployment times, maintenance costs, and provides PayPlug with ownership over its card acceptance solutions. The alliance builds on the long-standing partnership between Amadis and PayPlug.
PayPlug’s new application enables every store associate to bring the check out experience to the customer, the POI (point of interaction), wherever the consumer needs it to be, by enabling Android NFC COTS (Commercial-Off-The-Shelf) devices, such as smartphones, tablets or professional dedicated instruments.
“Amadis provided us with an effective way to offer our SME customers with innovative, new ways to accept card-present payments,” said Antoine Grimaud, PayPlug CEO. “We expect the solution to drive new revenue opportunities for our customers, while generating new points of payment acceptance in multiple countries, and enhancing the customer experience.
PayPlug’s new application includes all components of Amadis One (Amadis’ SoftPOS solution), in particular OLA (Open Level 2 API). OLA is an abstraction layer that allows an enterprise to run a payment application with the EMV Level 2 stack of any terminal manufacturer or SoftPOS - allowing enterprises to be fully payment device agnostic, independent of ecosystem, hardware and operating system.
“The new PayPlug application represents a new era for payments acceptance, and we are excited to be a part of their solution,” said Emmanuel Haydont, Amadis CEO. “With nexo protocols a reality for customers, Amadis simplifies nexo deployments and reduces costs, while helping enterprises accelerate deployments and access to multiple countries.”
“We are delighted to see PayPlug, and its customers, become the latest company that will benefit from our standardization work,” explains Jacques Soussana, nexo standards Secretary-General. “Our specifications and protocols remove the barriers traditionally present in the payment acceptance ecosystem, including within non-traditional environments such as mobile acceptance platforms like smartphones, tablets and COTS.”
To make the solution more interoperable, PayPlug’s application needed to effectively integrate with nexo payment standards. Amadis simplified implementation with its open, standards-based off-the-shelf framework that is nexo compliant.
About PayPlug
PayPlug is the French omnichannel pay-by-card solution for SMEs. Since 2012, it has been offering an innovative and easy to use alternative to traditional market players: among other things, the fintech relies on its unique ecosystem of partners and integrated features to simplify all things related to payments for its 15,000 customers, retailers and e-merchants in Europe. After acquiring the status of Payment Institution approved by the ACPR Banque de France, PayPlug joined the BPCE group in April 2017. Over the last three years, PayPlug has experienced nearly 100% growth per year. www.payplug.com
About nexo standards
nexo standards is the association dedicated to removing the barriers present in today’s fragmented global payment acceptance ecosystem. It enables fast, borderless and global payments acceptance by standardizing the exchange of data between all payment acceptance stakeholders. The nexo specifications and messaging protocols adhere to ISO 20022 standards, are universally applicable and fully open. www.nexo-standards.org/
About Amadis
Amadis is a leader in compliant payment software technology, with its software running on more than 40 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment acceptance software technology options based on the most efficient available standards, independent of hardware, retail vertical segment, or geography. The company brings an elite, experienced software team to the industry and enables solutions for international fintech, processors and merchants in over 23 countries. Learn more at www.amadis.ca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005013/en/
Contact information
Tina Meunier Agence : Hopscotch for Pay Plug
payplug@hopscotch.fr
01 58 65 01 21
David Finkelstein - The DFI Group (for Amadis)
david@thedfigroup.net
+1 416-300-4150
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom